Evaluate’s Brian Bock brings market data to an @alvarezmarsal fireside chat on biotech IPO and M&A readiness, with Eduardo Schur, Marcos Cortes and fellow panelists.

When: Wednesday, Nov. 18, noon to 1 p.m. ET

Register to join live: vist.ly/5rqri

IPO, acquisition or both? Biotech companies are weighing paths to liquidity and growth, and readiness shapes every option.

Join Evaluate and @alvarezmarsal on Nov. 18. Brian Bock sets the scene with data.

Register to hear how: vist.ly/5rqrh

BIO-Europe is around the corner. Evaluate, part of @NorstellaCo, can help you prep: find the right partners, run due diligence and valuation, and sharpen your negotiation strategy with data.

Booth 8-56, Nov. 9 to 11, or book a meeting: vist.ly/5rnnu

#BIOEurope

Retatrutide, Giredestrant, and Povetacicept are among the 60+ noteworthy drugs seeking approval in 2027. With 43 introducing new drug classes, 27 could change standards of care. Join Evaluate analysts on Nov. 12 at 3 p.m. GMT | 10 a.m. ET. Register: vist.ly/5rncy

Projecting that a new product will capture a certain share of patients? Tie the number to something that has already happened in the market.

Andrew Ward explains why analogs give assumptions a real-world reference. vist.ly/5rmf4

Join us on Nov. 12 as analysts Piotr Lis and Nkiru Ibeanu explore key questions on drug launches shaping 2027. Discover market impacts, new entrants, crucial decisions, and hidden assets. Free to attend! vist.ly/5rg2x

22 novel FDA approvals in Q3 2026, up from 13 in Q2. Evaluate Pharma’s consensus puts the cohort at $31B in 2032 sales. Paul Verdin on the new drugs ready to hit the market in @Nature: vist.ly/5rfv3

2027 is set to be a standout year for drug launches, with nearly two-thirds being first-in-class. Key candidates include Lilly's retatrutide, Roche's giredestrant, and Vertex's povetacicept. Join us on Nov. 12 for a 45-minute overview.

Register: vist.ly/5rd3h

Daniel Chancellor of @NorstellaCo moderates “Unlocking Pharma’s Productivity Potential” at BIO-Europe with M Ventures, Novo Nordisk, Blackstone Life Sciences and the EMA.

Nov. 9, 11 a.m. in Cologne.
Book a meeting: vist.ly/5rc8e

#BIOEurope

Two pieces of launch advice from Andrew Ward: drive your forecast with commercial strategy, and stay flexible on resourcing.

See how J+D Forecasting supports it: vist.ly/5r5p5

Evaluate Spotlight Ep.05: Advanced Therapies is now live!

Advanced therapy pipeline growth has slowed, but dealmaking and funding remain strong. @amandamicklus and @SydneyEnokawa discuss in vivo CAR-T, major deals, and what's next. ▶️

Watch now: vist.ly/5qyzw

Forecasting doesn’t look the same at every stage of a product’s life.

Andrew Ward explains why: as investment, resources, and stakeholder attention grow toward launch, the forecast has to become more robust to keep up.

vist.ly/5qy8p

Evaluate Spotlight Ep.03: Immunology is live!

Explore the trends, deals, and innovations shaping one of pharma’s fastest-growing therapy areas.

▶️ Watch now: vist.ly/5qvgf

Patient splits weren’t a finance priority, so the forecast grouped everyone together.

Andrew Ward on why a commercial lens keeps forecasts flexible and aligned with product strategy. vist.ly/5qnzm

We’re heading to BIO-Europe with @NorstellaCo in Cologne, Nov. 9 to 11. Stop by booth 8-56 in Hall 8 or book a meeting beforehand to get deal-ready for your BD&L conversations: vist.ly/5qh3a

#BIOEurope

Two promising opportunities. Which one has the stronger case?

Compare companies and assets across forecasts, market potential, catalysts, competition, and deal activity to uncover the signals behind each opportunity.

See how the opportunities stack up. vist.ly/5qgsv

$31B. That’s the 2032 sales forecast for the drugs the FDA approved in Q3 2026.

22 novel approvals, the busiest quarter of the year so far. Paul Verdin’s analysis in Nature: vist.ly/5qgji

"I consider myself an expert; I’ve been doing this for decades and can now do it in 10 minutes." – a Business Development Strategist at a global med-tech company on Atlas CI from @NorstellaCo, an AI agent for competitive intelligence.

Learn more: vist.ly/5qciv

Weeks to months of competitive pipeline research. A skeptic did it in 10 minutes.

A Business Development Strategist with decades of experience got a very similar output from @NorstellaCo Atlas CI, an AI agent for competitive intelligence.

Learn more: vist.ly/5qa2v

How can analogs help forecasters plan for new product launches?

Andrew Ward explains why they ground a forecast in what has already happened in the market, and how a group of similar products shows the range of performance to expect. vist.ly/5q767